The TOPCARE-DCM trial was one of the first studies demonstrating an improvement in LVEF and decrease in NT-proBNP following intracoronary infusion of bone marrow-derived cells (BMCs) in patients with non-ischemic DCM [87]. This evidence concerns the gene NPPB and familial dilated cardiomyopathy.